Marshall Wace LLP Raises Stock Position in Krystal Biotech, Inc. $KRYS

Marshall Wace LLP grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 552.5% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 112,382 shares of the company’s stock after purchasing an additional 95,158 shares during the period. Marshall Wace LLP’s holdings in Krystal Biotech were worth $15,448,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KRYS. Geode Capital Management LLC lifted its position in Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after acquiring an additional 7,194 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after purchasing an additional 365,304 shares in the last quarter. Braidwell LP increased its position in shares of Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company’s stock worth $72,254,000 after purchasing an additional 200,244 shares in the last quarter. Norges Bank purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at about $38,861,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock valued at $45,168,000 after purchasing an additional 7,344 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $234.64 on Wednesday. The stock has a fifty day moving average price of $200.23 and a 200 day moving average price of $164.51. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $241.65. The company has a market cap of $6.80 billion, a PE ratio of 35.18 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to the consensus estimate of $93.72 million. Analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 13.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Bank of America raised their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Chardan Capital lifted their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).